Effects of metformin and short-term lifestyle modification on the improvement of male hypogonadism associated with metabolic syndrome

Minerva Endocrinologica

Volumn 35, Issue 3, 2010, Pages 145-152

  Casulari, L Agusto ^a   Caldas, A D A ^b   Domingues Casulari Motta, L ^a   Lofrano Porto, A ^a,c  

^a HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^b Hospital das Forcas Armadas Brasilia   (Brazil)

^c UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Hypogonadism; Insulin resistance; Metabolic syndrome X; Metformin

Indexed keywords

FOLLITROPIN; INSULIN; METFORMIN; TESTOSTERONE;

ADULT; ARTICLE; BLOOD SAMPLING; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; FOLLITROPIN BLOOD LEVEL; GONAD FUNCTION; HUMAN; HYPOGONADISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MALE; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; TESTIS FUNCTION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; BODY MASS INDEX; DIET, REDUCING; HUMANS; HYPOGLYCEMIC AGENTS; HYPOGONADISM; LIFE STYLE; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; PHYSICAL FITNESS; PROSPECTIVE STUDIES; TESTOSTERONE; YOUNG ADULT;

EID: 78751623583     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 2002;102:151-66.
2. Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril 2006;85:1319-40.
3. Kapoor D, Jones TH. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging 2008;25:357-69.
4. Shabsigh R, Arver S, Channer KS, Eardley I, Fabbri A, Gooren L et al. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract 2008;62:791-8.
5. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl2009;32:587-98.
6. Caldas ADA, Porto AL, Motta LDC, Casulari LA. Relationship between insulin and hypogonadism in men with metabolic syndrome. Arq Bras Endocrinol Metab 2009;53:1005-11.
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from plasma glucose e and insulin concentrations in man. Diabetologia 1985;28:412-9.
8. Glass AR, Swerdloff RS, Bray GA, Dahms W, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab 1977;45:1211-9.
9. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993;76:1140-6.
10. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005;174:827-34. (Pubitemid 41140604)
11. Kapoor D, Malkint CJ, Channert KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005;63:239-50. (Pubitemid 41233438)
12. Lima N, Cavaliere H, Knobel M, Halpern A, Medeiros-Neto G. Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. Int J Obes Relat Metab Disord 2000;24:1433-7.
13. Zumoff B, Strain GW, Miler LK, Rosner W, Senie R, Seres DS et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990;71:929-31.
14. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002;87:4522-7.
15. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi E et al. Increase insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005;90:2636-41.
16. Gatti A, Mandosi E, Fallarino M, Radicioni A, Morini E, Maiani F et al. Metabolic syndrome (SM) and erectile dysfunction (ED) among obese non diabetic subjects. J Endocrinol Invest 2009;32:542-5.
17. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997;82:682-5.
18. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005;90:2618-23.
19. Chen RY, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab 2006;8:429-35.
20. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91:843-50.
21. Corona G, Mannucci E, Forti G, Maggi M. Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a therapy for diabetes? Int J Androl 2009;32:431-41.
22. Stanik S, Dornfeld LP, Maxwell MH, Viosca SP, Korenman SG. The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab 1981;53:828-32. (Pubitemid 13238668)
23. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004;6:208-15. (Pubitemid 38559701)
24. Strain G, Zumoff B, Rosner W, Pi-Sunyer X. The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss. J Clin Endocrinol Metab 1994;70:1173-6.
25. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-41.
26. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003;51:101-15.
27. Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 2003;52:1126-8.
28. de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab 2005;7:211-5.
29. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002; 167(2 Pt 1):624-9.
30. Holbrook JM, Cohen PG. Aromatase inhibition for the treatment of idiopathic hypogonadotropic hypogonadism in men with premature ejaculation. South Med J 2003;96:544-7.
31. de Ronde W. Therapeutic uses of aromatase inhibitors in men. Curr Opin Endocrinol Diabetes Obes 2007;14:235-40.
32. Hammoud A, Gibson M, Hunt SC, Adams TD, Carrell DT, Kolotkin RL et al. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab 2009,94:1329-32.
33. Bastounis EA, Karayiannakis AJ, Syrigos K, Zbar A, Makri GG, Alexiou D. Sex hormone changes in morbidly obese patients after vertical banded gastroplasty. Eur Surg Res 1998;30:43-7.
34. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157-67.
35. Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 2005;7:654-65.
36. Sharma ST, Wickham EP 3rd, Nestler JE. Changes in glucose tolerance with metformin treatment in polycystic syndrome: a retrospective analysis. Endocr Pract 2007;13:373-9.
37. Domingues L, Casulari LA. Insulin and insulin-like growth factors in the polycystic ovaries syndrome. Ars Cvrandi 2000;33:44-56.
38. Motta LDC, Casulari LA. Polycystic ovaries syndrome: pathophisiology and treatment. Brasília Med 2000;37:31-7.
39. Ozata M, Oktenli C, Bingol N, Ozdemir IC. The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Obes Res 2001;9:662-7.
40. Shegem NS, Alsheek Nasir AM, Batieha AM, El-Shanti H, Ajlouni KM. Effects of short term metformin administration on androgens in diabetic men. Saudi Med J 2004;25:75-8.
41. Shegem NS, Nasir AM, Jbour AK, Batieha AM, El-Khateeb MS, Ajlouni KM. Effects of short term metformin administration on androgens in normal men. Saudi Med J 2002;23:934-7.
42. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1414-28.
43. Vilar L, Freitas MC, Albuquerque JL, Botelho CA, Egito CS, Arruda MJ et al. The role of non-invasive dynamic tests in the diagnosis of Cushing's syndrome. J Endocrinol Invest 2008;31:1008-13.
44. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
45. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-¬IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract 2006;72:219-20.
46. Lin T, Haskell J, Vinson N, Terracio L. Characterization of insulin and insulin-like growth factor I receptors of purified Leydig cells and their role in steroidogenesis in primary culture: a comparative study. Endocrinology 1986;119:1641-7.
47. Bebakar WM, Honour JW, Foster D, Liu YL, Jacobs HS. Regulation of testicular function by insulin and transforming growth factor-beta. Steroids 1990;55:266-70.
48. Santos RF, Nomizo R, Wajhenberg BL, Reaven G.M, Azhar S. Changes in insulin receptor tyrosine kinase activity associated with metformin treatment of type 2 diabetes. Diabete Metab 1995;21:274-80.
49. Magkos F, Yannakoulia M, Chan JL, Mantzoros CS. Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr 2009;29:223-56.
50. Amatruda JM, Hochstein M, Hsu TH, Lockwood DH. Hypothalamic and pituitary dysfunction in obese males. Int J Obes 1982;6:183-9.